9.37
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché GRFS Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$9.16
Aprire:
$9.25
Volume 24 ore:
754.83K
Relative Volume:
1.14
Capitalizzazione di mercato:
$2.45B
Reddito:
$7.94B
Utile/perdita netta:
$225.54M
Rapporto P/E:
28.40
EPS:
0.3299
Flusso di cassa netto:
$709.16M
1 W Prestazione:
-0.95%
1M Prestazione:
-5.92%
6M Prestazione:
+34.82%
1 anno Prestazione:
+7.83%
Grifols Sa Adr Stock (GRFS) Company Profile
Nome
Grifols Sa Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta GRFS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
GRFS
Grifols Sa Adr
|
9.37 | 6.23B | 7.94B | 225.54M | 709.16M | 0.3299 |
|
LLY
Lilly Eli Co
|
862.86 | 757.06B | 59.42B | 18.41B | -50.20M | 20.22 |
|
JNJ
Johnson Johnson
|
188.87 | 455.48B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
218.04 | 403.13B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
123.79 | 235.26B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
85.98 | 215.51B | 63.99B | 19.05B | 14.72B | 7.5596 |
Grifols Sa Adr Stock (GRFS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-12 | Ripresa | Morgan Stanley | Overweight |
| 2024-03-12 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-04-12 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-16 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2023-01-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-04-08 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-11-05 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-10-19 | Downgrade | Barclays | Overweight → Underweight |
| 2021-10-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-06-14 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2021-04-20 | Iniziato | Deutsche Bank | Hold |
| 2021-03-23 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2021-03-11 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2020-10-01 | Aggiornamento | Citigroup | Sell → Neutral |
| 2020-06-09 | Downgrade | Citigroup | Neutral → Sell |
| 2020-06-09 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2020-03-25 | Downgrade | Citigroup | Buy → Neutral |
| 2019-06-27 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-02-08 | Downgrade | Berenberg | Buy → Hold |
| 2018-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2018-06-01 | Iniziato | Barclays | Overweight |
| 2017-10-31 | Iniziato | Citigroup | Buy |
| 2017-06-30 | Downgrade | Goldman | Buy → Neutral |
| 2017-04-06 | Iniziato | BofA/Merrill | Buy |
| 2017-01-03 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2016-02-09 | Aggiornamento | Berenberg | Hold → Buy |
| 2016-01-04 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2015-12-02 | Downgrade | HSBC Securities | Buy → Hold |
| 2015-11-20 | Downgrade | Berenberg | Buy → Hold |
| 2015-04-28 | Downgrade | Berenberg | Buy → Hold |
Mostra tutto
Grifols Sa Adr Borsa (GRFS) Ultime notizie
Grifols slips as board rebuffs Brookfield’s $6.8B offer (update) - MSN
Grifols, S.A.American Depositary Shares (Nasdaq:GRFS) Stock Quote - FinancialContent
Validea Joseph Piotroski Strategy Daily Upgrade Report10/10/2025 - Nasdaq
Arm Holdings PLC ADRhedged (BATS:ARMH) Short Interest Down 33.3% in September - Defense World
Grifols Stock: Significant Upside Is Materializing (NASDAQ:GRFS) - Seeking Alpha
GRDLY Stock Price, Quote and News - Markets.com
Grifols (NASDAQ:GRFS) Share Price Crosses Above 200-Day Moving Average – Should You Sell? - Defense World
Plasma Derived Medicine Market to Reach USD 37.4 Billion by 2034, Growing at 8.05% CAGR - GlobeNewswire Inc.
Grifols Announces Interim Dividend for 2025 - The Globe and Mail
CNH Industrial NV (NYSE: CNH) Stock Forecast: Bearish Sentiment Points To -15.21% Downside In 2025 - stocksregister.com
Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday - Benzinga
Oppenheimer Asset Management Inc. Acquires 23,980 Shares of Grifols, S.A. (NASDAQ:GRFS) - Defense World
ADMA Biologics Vs. Grifols: Which Plasma Therapy Stock Is The Better Buy? - Barchart.com
ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy? - The Globe and Mail
Grifols: If This Works Out, It Has Massive Upside (NASDAQ:GRFS) - Seeking Alpha
Grifols S.A. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
6 undervalued stocks with low beta - Morningstar
Deutsche Bank raises Grifols SA price target to EUR11.00 - Investing.com
Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale (GRFS) - Seeking Alpha
Grifols: More Attractive Than In A Very Long Time (NASDAQ:GRFS) - Seeking Alpha
Grifols Stock Declines After Brookfield Drops Buyout Offer - Yahoo Finance
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8% - Yahoo Finance
Invesco Nasdaq Biotechnology ETF Holdings - Quiver Quantitative
Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down (NASDAQ:GRFS) - Seeking Alpha
Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday - Yahoo Finance
Grifols: Going Private? Brookfield On The Scene (OTCMKTS:GIFLF) - Seeking Alpha
Grifols 2023 Annual Report on Form 20-F filed with the SEC - PR Newswire
Grifols S.A. (GRFS – ADR ADR Class B) Shares Decline Again After Gotham City Research Issues Another Critical Report – Hagens Berman - ACCESS Newswire
AMBAR, an Encouraging Alzheimer's Trial That Raises Questions - Frontiers
The 10 Most-Bought and Most-Sold European Stocks | Morningstar UK - Morningstar Canada
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? - Yahoo Finance
ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action InvestigationGRFS, GIKLY, GIFOF, GIFLF - PR Newswire
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Grifols, S.A. - GlobeNewswire
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action InvestigationGRFS, GIKLY, GIFOF, GIFLF - FinancialContent
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action InvestigationGRFS, GIKLY, GIFOF, GIFLF - FinancialContent
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Grifols, - GlobeNewswire
GRFS Stock Quote Price and Forecast - CNN
BreakingviewsShort attack intensifies Grifols’ health problem - Reuters
Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023 - PR Newswire
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada - PR Newswire Canada
8 Newly Undervalued 5-Star Stocks - Morningstar
Grifols 2020 Annual Report on Form 20-F filed with the SEC on April 9, 2021 - PR Newswire
Grifols Class B: Buy The Recovery In The U.S. Plasma Business (NASDAQ:GRFS) - Seeking Alpha
Grifols SA Share Price ADR each Representing 1 Non Voting B Share - Hargreaves Lansdown
Grifols, S.A.: Target Price Consensus and Analysts Recommendations | GRF | ES0171996087 - MarketScreener
Grifols SA: Shareholders Board Members Managers and Company Profile | ES0171996012 - MarketScreener
These European companies benefit from high health-care prices in the U.S. - MarketWatch
How International Is Your Foreign-Stock Fund? - Morningstar
GRFS or ORINY: Which Is the Better Value Stock Right Now? - Yahoo News Canada
GRF Stock Price and Chart — BME:GRF - TradingView
Top 75 Healthcare Dividend Stocks To Invest In - Insider Monkey
Grifols Sa Adr Azioni (GRFS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):